Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
9.79
-0.18 (-1.81%)
Nov 21, 2024, 12:43 PM EST - Market open
Theravance Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 63.19 | 57.42 | 51.35 | 55.31 | 71.86 | 73.41 | Upgrade
|
| Revenue Growth (YoY) | 15.93% | 11.84% | -7.17% | -23.03% | -2.12% | 21.61% | Upgrade
|
| Cost of Revenue | 36.5 | 40.62 | 63.39 | 193.66 | 260.95 | 219.25 | Upgrade
|
| Gross Profit | 26.69 | 16.8 | -12.05 | -138.35 | -189.1 | -145.83 | Upgrade
|
| Selling, General & Admin | 66.17 | 70.1 | 67.07 | 99.3 | 108.53 | 106.08 | Upgrade
|
| Operating Expenses | 66.17 | 70.1 | 67.07 | 99.3 | 108.53 | 106.08 | Upgrade
|
| Operating Income | -39.48 | -53.29 | -79.12 | -237.64 | -297.63 | -251.92 | Upgrade
|
| Interest Expense | -2.53 | -2.35 | -6.37 | -8.55 | -8.55 | -31.86 | Upgrade
|
| Interest & Investment Income | 5.76 | 9.06 | 6.74 | 2.01 | 4.74 | 8.2 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | 33.71 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.9 | -0.9 | -0.3 | 0.2 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -1.61 | - | Upgrade
|
| EBT Excluding Unusual Items | -36.18 | -46.53 | -79.65 | -245.08 | -303.34 | -241.68 | Upgrade
|
| Merger & Restructuring Charges | - | -2.74 | -12.84 | -20.14 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 2.71 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -3.03 | - | - | - | Upgrade
|
| Pretax Income | -40.69 | -49.27 | -92.82 | -265.22 | -303.34 | -241.68 | Upgrade
|
| Income Tax Expense | 8.71 | 5.92 | 0.01 | -0.15 | -8.52 | -5.22 | Upgrade
|
| Earnings From Continuing Operations | -49.4 | -55.19 | -92.82 | -265.07 | -294.82 | -236.46 | Upgrade
|
| Earnings From Discontinued Operations | - | - | 964.96 | 65.65 | 16.81 | - | Upgrade
|
| Net Income | -49.4 | -55.19 | 872.13 | -199.43 | -278.02 | -236.46 | Upgrade
|
| Net Income to Common | -49.4 | -55.19 | 872.13 | -199.43 | -278.02 | -236.46 | Upgrade
|
| Shares Outstanding (Basic) | 49 | 55 | 74 | 69 | 62 | 56 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 55 | 74 | 69 | 62 | 56 | Upgrade
|
| Shares Change (YoY) | -18.30% | -24.85% | 5.95% | 11.41% | 12.11% | 3.04% | Upgrade
|
| EPS (Basic) | -1.01 | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 | Upgrade
|
| EPS (Diluted) | -1.01 | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 | Upgrade
|
| Free Cash Flow | -12.31 | -29.49 | -187.56 | -211.26 | -257.02 | -241.37 | Upgrade
|
| Free Cash Flow Per Share | -0.25 | -0.53 | -2.55 | -3.04 | -4.12 | -4.34 | Upgrade
|
| Gross Margin | 42.23% | 29.26% | -23.46% | -250.12% | -263.16% | -198.65% | Upgrade
|
| Operating Margin | -62.47% | -92.80% | -154.09% | -429.65% | -414.19% | -343.14% | Upgrade
|
| Profit Margin | -78.18% | -96.11% | 1698.54% | -360.55% | -386.90% | -322.08% | Upgrade
|
| Free Cash Flow Margin | -19.47% | -51.35% | -365.29% | -381.96% | -357.68% | -328.78% | Upgrade
|
| EBITDA | -39.69 | -53.19 | -76.08 | -232.83 | -294 | -248.93 | Upgrade
|
| EBITDA Margin | -62.81% | -92.62% | -148.18% | - | - | - | Upgrade
|
| D&A For EBITDA | -0.22 | 0.1 | 3.04 | 4.81 | 3.63 | 2.99 | Upgrade
|
| EBIT | -39.48 | -53.29 | -79.12 | -237.64 | -297.63 | -251.92 | Upgrade
|
| EBIT Margin | -62.47% | -92.80% | -154.09% | - | - | - | Upgrade
|
| Revenue as Reported | 63.19 | 57.42 | 51.35 | 55.31 | 71.86 | 73.41 | Upgrade
|
| Advertising Expenses | - | 5.1 | 8 | 9.3 | 6.3 | 2.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.